Pisani LF, Moriggi M, Gelfi C, Vecchi M, Pastorelli L. Proteomic insights on the metabolism in inflammatory bowel disease. World J Gastroenterol 2020; 26(7): 696-705 [PMID: 32116417 DOI: 10.3748/wjg.v26.i7.696]
Corresponding Author of This Article
Luca Pastorelli, DPhil, MD, Assistant Professor, Doctor, Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, Piazza Malan, San Donato Milanese 20097, Italy. luca.pastorelli@unimi.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Laura Francesca Pisani, Manuela Moriggi, Luca Pastorelli, Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese 20097, Italy
Cecilia Gelfi, Department of Biomedical Science for Health, University of the Study of Milan, IRCCS Istituto Ortopedico Galeazzi, Milan 20122, Italy
Maurizio Vecchi, Gastroenterology and Endoscopy Unit, IRCCS Ca' Granda Foundation, Policlinico Hospital, University of the Study of Milan, Milan 20122, Italy
Luca Pastorelli, Department of Biomedical Science for Health, University of the Study of Milan, Milan 20122, Italy
Author contributions: Pisani LF performed the majority of the writing; Moriggi M prepared the figure and wrote the technical proteomic paragraphs; Vecchi M provided the input in writing the review; Gelfi C revised the review and gave her support as proteomics expert; and Pastorelli L revised the review and gave his support as clinical expert.
Supported byItaly’s Ministero Italiano della Salute (Italian Ministry of Health Grant), No. GR-2016-02364736.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Luca Pastorelli, DPhil, MD, Assistant Professor, Doctor, Gastroenterology and Digestive Endoscopy Unit, IRCCS Policlinico San Donato, Piazza Malan, San Donato Milanese 20097, Italy. luca.pastorelli@unimi.it
Received: November 25, 2019 Peer-review started: November 25, 2019 First decision: December 23, 2019 Revised: January 2, 2020 Accepted: February 10, 2020 Article in press: February 10, 2020 Published online: February 21, 2020
Core Tip
Core tip: Patients' heterogeneity is a hallmark for inflammatory bowel diseases (IBD). Some patients present limited bowel involvement and a mild course of the disease, others develop very extensive, aggressive disease and variable response to therapy. In IBD, there is a great need of patient stratification and of new biomarkers as part of a personalized medicine approach to patient care. Biological therapies are more and more widely used for IBD patients, because of their efficacy in patient’s refractory to other drugs; still, biological treatments fail in 20%-40% of patients and, to date, no reliable clinical or molecular predictor of response to biological therapeutic strategy has been described. This review aims to collect the "omics" approach for research of serological biomarkers of diagnosis, response to specific biological therapies in the IBD field.
